Q4 2020

Filed Mar 12, 2021 · 10-K · 71 days after period end · 0001564590-21-012607

Q4 2020 · 10-K

Revenue

$380.00K

±0.0% vs Q4 2019

Net Income

-$20.42M

N/M vs Q4 2019

EPS Diluted

-$0.44

N/M vs Q4 2019

Operating Income-$19,860,000N/M

Operating Cash Flow

Same quarter

Metric	Q4 2020	Q4 2019	Q4 2018	Q4 2017
Revenue	$380.00K	$380.00K	$380.00K	$1.19M
Net Income	-$20.42M	-$14.00M	-$18.84M	-$19.10M
EPS Diluted	-$0.44	-$0.44	$0.70	-$0.80

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR